Harmony Biosciences公布2025年强劲财报,重申2026年净收入指引超10亿美元

美股速递
Feb 24

Harmony Biosciences Holdings, Inc.(简称Harmony Biosciences)近日披露了其2025年度财务业绩,表现显著超出市场预期。公司同时重申了对2026财年的积极展望,预计净收入将突破10亿美元大关。

财务数据显示,公司在2025年实现了强劲的收入增长与盈利能力提升,主要得益于核心产品市场的持续扩张及运营效率的优化。管理层在业绩说明中强调,这一成果为2026年的战略目标奠定了坚实基础。

基于当前业务势头与管线进展,Harmony Biosciences确认2026年净收入指引维持在10亿美元以上,反映出管理层对业务增长潜力的坚定信心。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10